Literature DB >> 27644076

Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes.

Paul K Crane1, Rod L Walker2, Joshua Sonnen3, Laura E Gibbons4, Rebecca Melrose5, Jason Hassenstab6, C Dirk Keene7, Nadia Postupna7, Thomas J Montine7, Eric B Larson2.   

Abstract

We evaluated associations between glucose and dementia-related neuropathologic findings among people without diabetes treatment history to elucidate mechanisms of glucose's potential effect on dementia. We used glucose and hemoglobin A1c values to characterize glucose exposures over 5 years before death (primary) and age bands from 55-59 through 80-84 (secondary). Autopsy evaluations included Braak stage for neurofibrillary tangles, Consortium to Establish a Registry for Alzheimer's Disease grade for neuritic plaques, macroscopic infarcts including lacunar infarcts, Lewy bodies, cerebral microinfarcts, and hippocampal sclerosis. Of 529 who came to autopsy, we included 430 with no history of diabetes treatment. We found no associations between glucose levels and Braak stage or Consortium to Establish a Registry for Alzheimer's Disease grade. There was a suggestion of a relationship between glucose and hippocampal sclerosis, although this was inconsistent across analyses. There was higher risk of Lewy bodies in substantia nigra and locus ceruleus with higher glucose levels in age band analyses. We did not find interactions between glucose levels, neuropathologic findings, and dementia. The mechanism by which glucose may impact dementia risk is still unknown.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glucose; Hippocampal sclerosis; Lewy bodies; Neuritic plaques; Neurofibrillary tangles; Neuropathology

Mesh:

Substances:

Year:  2016        PMID: 27644076      PMCID: PMC5441884          DOI: 10.1016/j.neurobiolaging.2016.07.021

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  45 in total

Review 1.  Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors:  E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 2.  Dementia with Lewy bodies.

Authors:  James B Leverenz; Ian G McKeith
Journal:  Med Clin North Am       Date:  2002-05       Impact factor: 5.456

3.  Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.

Authors:  G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

4.  Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.

Authors:  Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

5.  Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE.

Authors:  Nadia Postupna; Christopher Dirk Keene; Paul K Crane; Luis F Gonzalez-Cuyar; Joshua A Sonnen; Jessica Hewitt; Samantha Rice; Kimberly Howard; Kathleen S Montine; Eric B Larson; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-02       Impact factor: 3.685

6.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles.

Authors:  David A Bennett; Philip L De Jager; Sue E Leurgans; Julie A Schneider
Journal:  Neurology       Date:  2009-04-28       Impact factor: 9.910

7.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

8.  Glucose levels and risk of dementia.

Authors:  Paul K Crane; Rod Walker; Rebecca A Hubbard; Ge Li; David M Nathan; Hui Zheng; Sebastien Haneuse; Suzanne Craft; Thomas J Montine; Steven E Kahn; Wayne McCormick; Susan M McCurry; James D Bowen; Eric B Larson
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

9.  Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

Authors:  James B Leverenz; Ronald Hamilton; Debby W Tsuang; Aimee Schantz; Darcy Vavrek; Eric B Larson; Walter A Kukull; Oscar Lopez; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Randall Woltjer; Christopher Clark; John Q Trojanowski; Thomas J Montine
Journal:  Brain Pathol       Date:  2008-01-29       Impact factor: 6.508

10.  Glycemic status and brain injury in older individuals: the age gene/environment susceptibility-Reykjavik study.

Authors:  Jane S Saczynski; Sigurdur Siggurdsson; Palmi V Jonsson; Gudny Eiriksdottir; Elin Olafsdottir; Olafur Kjartansson; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Diabetes Care       Date:  2009-06-09       Impact factor: 19.112

View more
  9 in total

1.  Ophthalmology-Based Neuropathology Risk Factors: Diabetic Retinopathy is Associated with Deep Microinfarcts in a Community-Based Autopsy Study.

Authors:  Cecilia S Lee; Eric B Larson; Laura E Gibbons; Caitlin S Latimer; Shannon E Rose; Leanne L Hellstern; C Dirk Keene; Paul K Crane
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  Review: Relationship of type 2 diabetes to human brain pathology.

Authors:  J J Pruzin; P T Nelson; E L Abner; Z Arvanitakis
Journal:  Neuropathol Appl Neurobiol       Date:  2018-03-04       Impact factor: 8.090

Review 3.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

4.  Insulin resistance among obese middle-aged is associated with decreased cerebrovascular reactivity.

Authors:  Olivia H Frosch; Po Lai Yau; Ricardo S Osorio; Henry Rusinek; Pippa Storey; Antonio Convit
Journal:  Neurology       Date:  2017-06-14       Impact factor: 9.910

5.  Fine Particulate Matter and Markers of Alzheimer's Disease Neuropathology at Autopsy in a Community-Based Cohort.

Authors:  Rachel M Shaffer; Ge Li; Sara D Adar; C Dirk Keene; Caitlin S Latimer; Paul K Crane; Eric B Larson; Joel D Kaufman; Marco Carone; Lianne Sheppard
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

6.  Assessing robustness of hazard ratio estimates to outcome misclassification in longitudinal panel studies with application to Alzheimer's disease.

Authors:  Le Wang; Rebecca A Hubbard; Rod L Walker; Edward B Lee; Eric B Larson; Paul K Crane
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 7.  Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.

Authors:  Christian Benedict; Claudia A Grillo
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

Review 8.  The Therapeutic Potential of Metformin in Neurodegenerative Diseases.

Authors:  Carola Rotermund; Gerrit Machetanz; Julia C Fitzgerald
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-19       Impact factor: 5.555

9.  Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation).

Authors:  Tara Sedlak; Romana Herscovici; Galen Cook-Wiens; Eileen Handberg; Janet Wei; Chrisandra Shufelt; Vera Bittner; Steven E Reis; Nathaniel Reichek; Carl Pepine; C Noel Bairey Merz
Journal:  J Am Heart Assoc       Date:  2020-04-09       Impact factor: 6.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.